000842643 001__ 842643
000842643 005__ 20210129232417.0
000842643 0247_ $$2Handle$$a2128/16850
000842643 037__ $$aFZJ-2018-00850
000842643 041__ $$aEnglish
000842643 1001_ $$0P:(DE-Juel1)133346$$aSchmitz, Sabine$$b0$$eCorresponding author
000842643 1112_ $$a14th International Congress of Radiation Research$$cWarsaw$$d2011-08-28 - 2011-09-01$$gICRR$$wPoland
000842643 245__ $$aChromosomal radiosensitivity of prostate cancer patients and healthy donors analysed by FISH
000842643 260__ $$c2011
000842643 3367_ $$033$$2EndNote$$aConference Paper
000842643 3367_ $$2BibTeX$$aINPROCEEDINGS
000842643 3367_ $$2DRIVER$$aconferenceObject
000842643 3367_ $$2ORCID$$aCONFERENCE_POSTER
000842643 3367_ $$2DataCite$$aOutput Types/Conference Poster
000842643 3367_ $$0PUB:(DE-HGF)24$$2PUB:(DE-HGF)$$aPoster$$bposter$$mposter$$s1517208209_23350$$xAfter Call
000842643 520__ $$aBackground: It is known that about 10 % of cancer patients show severe clinical side effects during and after radiotherapy due to enhanced sensitivity to ionizing ra-diation. Identification of those radiosensitive individuals by an in vitro assay before onset of treatment would be of great impact for successful radiotherapy.In this study we compared the radiosensitivity of the chromosomes 2, 11 and 17 in prostate cancer patients with and without severe side effects after radiotherapy and in age-matched healthy donors (control cohort). The chromosomal radiosensitivity of peripheral blood lymphocytes (PBL) of radiotherapy patients was used as predictive parameter for clinical side effects.Material und Methods: Each cohort consisted of at least 10 donors. PBL were irra-diated ex vivo with 0.5, 1 und 2 Gy (Cs-137 -rays) in the G0-Phase of the cell cycle. We analyzed the radiosensitivity of the chromosomes 2, 11 and 17 by scoring of 100 FISH painted metaphases for each dose point. Statistical analyses were performed by non-parametric Mann-Whitney test, by test of variances (ANOVA) and Chi-square goodness-of-fit test at a significance level of 0.05. Results: Analysis of the overall aberration yield revealed no significant differences between any donor groups. However, variance analyses showed significant differ-ences between the patient’s cohort and healthy donors for chromosomes 11 and 17 for all doses analyzed. In contrast, this was not true for chromosome 2. Furthermore, good correlations between chromosomes sizes (DNA content) and aberration yield were found.Conclusion: The cohort of prostate cancer patients can be distinguished from healthy donors due to variances of the aberration yields of the chromosomes 11 and 17. These chromosomes might be potential cytogenetic biomarkers for prostate can-cer patients in clinical studies.Funded by Dr. Erich-Schmitt -Foundation
000842643 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000842643 65027 $$0V:(DE-MLZ)SciArea-160$$2V:(DE-HGF)$$aBiology$$x0
000842643 7001_ $$0P:(DE-HGF)0$$aBrzozowska, Kinga$$b1
000842643 7001_ $$0P:(DE-HGF)0$$aPinkawa, Michael$$b2
000842643 7001_ $$0P:(DE-HGF)0$$aEble, Michael$$b3
000842643 7001_ $$0P:(DE-Juel1)133341$$aPomplun, Ekkehard$$b4
000842643 7001_ $$0P:(DE-Juel1)133469$$aKriehuber, Ralf$$b5$$ufzj
000842643 8564_ $$uhttps://juser.fz-juelich.de/record/842643/files/Schmitz%20et%20al%20ICRR%202011%20Warschau.pdf$$yOpenAccess
000842643 8564_ $$uhttps://juser.fz-juelich.de/record/842643/files/Schmitz%20et%20al%20ICRR%202011%20Warschau.gif?subformat=icon$$xicon$$yOpenAccess
000842643 8564_ $$uhttps://juser.fz-juelich.de/record/842643/files/Schmitz%20et%20al%20ICRR%202011%20Warschau.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000842643 8564_ $$uhttps://juser.fz-juelich.de/record/842643/files/Schmitz%20et%20al%20ICRR%202011%20Warschau.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000842643 8564_ $$uhttps://juser.fz-juelich.de/record/842643/files/Schmitz%20et%20al%20ICRR%202011%20Warschau.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000842643 8564_ $$uhttps://juser.fz-juelich.de/record/842643/files/Schmitz%20et%20al%20ICRR%202011%20Warschau.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000842643 909CO $$ooai:juser.fz-juelich.de:842643$$pdriver$$pVDB$$popen_access$$popenaire
000842643 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133346$$aForschungszentrum Jülich$$b0$$kFZJ
000842643 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b1$$kFZJ
000842643 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a S-US$$b1
000842643 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-HGF)0$$aRWTH Aachen$$b2$$kRWTH
000842643 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universitätsklinik für Strahlentherapie$$b2
000842643 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-HGF)0$$aRWTH Aachen$$b3$$kRWTH
000842643 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universitätsklinik für Strahlentherapie$$b3
000842643 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133469$$aForschungszentrum Jülich$$b5$$kFZJ
000842643 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000842643 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000842643 920__ $$lyes
000842643 9201_ $$0I:(DE-Juel1)S-US-20090406$$kS-US$$lSicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie$$x0
000842643 980__ $$aposter
000842643 980__ $$aVDB
000842643 980__ $$aUNRESTRICTED
000842643 980__ $$aI:(DE-Juel1)S-US-20090406
000842643 9801_ $$aFullTexts